Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
15 July 2020

The COVID-19 pandemic has exposed the fracture lines in societies worldwide. South Africa is no different. The poor are less able to protect themselves from the danger posed by the virus. Workers in factories, mines, and the service sector went back to their places of work following the lifting of the strictest lockdown measures, while office workers, typically better paid, can generally work from home. Living conditions in informal settlements make social distancing all but impossible, while the middle class can largely stay at home and stay safe to a much larger extent. With many businesses shutting down, downsizing or rethinking their business models, it is often small and medium, as well as informal sector businesses that are most affected.  

The impact of COVID-19 comes on the back of a society and economy that was already under significant pressure following years of low economic growth and poor government performance. Many commentators have already questioned the social compact South Africans made in the mid-1990s, which marked the end of the apartheid regime. These divisions have become more glaring, with some civil society organisations considering challenging the Minister of Finance’s adjustment budget in the Constitutional Court, because the budget might result in a roll-back of the progressive realisation of the socio-economic rights mandated in the Constitution.

In this first of four webinars, academics from the UFS as well as invited experts reflect on the constitutional commitment South Africans made to one another two and half decades ago. Is it time for a new deal? Should we collectively recommit ourselves to our existing deal? Do we interpret that deal in the same way today as we did more than two decades ago? How does the economic reality we face, particularly in the aftermath of the COVID-19 crisis, affect that deal? What are the economic realities we face, and whose are they? And how should we think about human development in the context of our deal? 

Come and join us from 14:00 to 15:30 on 21 July. 

RSVP to Sibongile Mlotya at MlotyaS@ufs.ac.za no later than 19 July, upon which you will receive a Business for Skype meeting invite.

Speakers:
Prof Danie Brand on ‘New deal’ or collective recommitment? The Constitution under COVID-19 and beyond

Prof Melanie Walker on Human development and the capability approach in COVID-19 times

Prof Lochner Marais on Reflections on continuities and discontinuities after COVID-19

Prof Philippe Burger on Viewing the realisation of socio-economic rights in a post-COVID-19 South Africa through an economic lens

 

Please also mark the following dates in your diaries for the second through fourth Reflection webinars:
Gender Inequalities and Gender-based Violence 28 July 14:00-15:30
The quality of our democracy under COVID-19 and beyond 13 August 14:00-15:30
Urban living post-COVID-19 27 August 14:00-15:30

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept